



NDA 20-702/S-037

Pfizer, Inc., Agent for Pfizer Ireland Pharmaceuticals
Attention: Christopher A. Graham
Director, Worldwide Regulatory Strategy
235 East 42nd Street 150/7/12
New York, NY 10017

Dear Mr. Graham:

Please refer to your supplemental new drug application dated March 31, 2003, received April 1, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lipitor (atorvastatin calcium) tablets.

We acknowledge receipt of your submission dated July 1, 2003.

This "Changes Being Effected" supplemental new drug application provides for the addition of a 5000-count bottle for the 20 mg strength and a 500-count bottle for the 40 and 80 mg strengths. Additionally, this supplement provides for revisions to the **HOW SUPPLIED** section of the Lipitor package insert to add these new presentations.

We completed our review of this supplemental new drug application. This application is approved, effective on the date of this letter, for use as recommended in the final printed labeling (FPL) submitted on July 1, 2003.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Margaret Simoneau, R.Ph., Regulatory Project Manager, at (301) 827-6411.

Sincerely,

{See appended electronic signature page}

David G. Orloff, M.D.
Director
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Mary Parks
9/29/03 03:24:08 PM
for Dr. Orloff